Welcome!

News Feed Item

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

NEW YORK, April 22, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02051452/Chemotherapy-Induced-Acral-Erythema-Hand-Foot-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 7
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 31
Apr 20, 2011: Advancell Initiates Clinical Phase IIb Study Of ATH008 In Hand-foot Syndrome 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
F. Hoffmann-La Roche Ltd. 32
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 32
Merck & Co., Inc. 33
Clinical Trial Overview of Merck & Co., Inc. 33
Cahaba Pharmaceuticals 34
Clinical Trial Overview of Cahaba Pharmaceuticals 34
Advancell 35
Clinical Trial Overview of Advancell 35
Clinical Trial Overview of Top Institutes / Government 36
Northwestern University 36
Clinical Trial Overview of Northwestern University 36
Cambridge University Hospitals NHS Foundation Trust 37
Clinical Trial Overview of Cambridge University Hospitals NHS Foundation Trust 37
Asan Medical Center 38
Clinical Trial Overview of Asan Medical Center 38
North Central Cancer Treatment Group 39
Clinical Trial Overview of North Central Cancer Treatment Group 39
Sun Yat-sen University 40
Clinical Trial Overview of Sun Yat-sen University 40
Case Comprehensive Cancer Center 41
Clinical Trial Overview of Case Comprehensive Cancer Center 41
Duke University 42
Clinical Trial Overview of Duke University 42
West Virginia University 43
Clinical Trial Overview of West Virginia University 43
University of California, San Francisco 44
Clinical Trial Overview of University of California, San Francisco 44
University of Wisconsin Madison 45
Clinical Trial Overview of University of Wisconsin Madison 45
Five Key Clinical Profiles 46
Appendix 60
Abbreviations 60
Definitions 60
Research Methodology 61
Secondary Research 61
About GlobalData 62
Contact Us 62
Disclaimer 62
Source 63

List of Tables

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 32
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 33
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cahaba Pharmaceuticals, 2014* 34
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Advancell, 2014* 35
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 36
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cambridge University Hospitals NHS Foundation Trust, 2014* 37
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 38
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 39
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 40
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 41
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 42
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by West Virginia University, 2014* 43
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 44
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014* 45

List of Figures
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 11
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 61

To order this report: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051452/Chemotherapy-Induced-Acral-Erythema-Hand-Foot-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We are an IT services solution provider and we sell software to support those solutions. Our focus and key areas are around security, enterprise monitoring, and continuous delivery optimization," noted John Balsavage, President of A&I Solutions, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, discussed the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
The financial services market is one of the most data-driven industries in the world, yet it’s bogged down by legacy CPU technologies that simply can’t keep up with the task of querying and visualizing billions of records. In his session at 20th Cloud Expo, Karthik Lalithraj, a Principal Solutions Architect at Kinetica, discussed how the advent of advanced in-database analytics on the GPU makes it possible to run sophisticated data science workloads on the same database that is housing the rich...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, discussed new ways of thinking and the approaches needed to address the emerging challenges of security i...
"We want to show that our solution is far less expensive with a much better total cost of ownership so we announced several key features. One is called geo-distributed erasure coding, another is support for KVM and we introduced a new capability called Multi-Part," explained Tim Desai, Senior Product Marketing Manager at Hitachi Data Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
DX World EXPO, LLC., a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.